View Full Company Profile

Azenta, Inc.

CIK: 933974 Filed: December 4, 2025 10-K

Key Highlights

  • Azenta helps healthcare and life sciences companies with biological sample storage/management and automation solutions.
  • The company operates through two main business segments: Sample Management Solutions and Multiomics.
  • Azenta is undergoing a transformation plan to cut costs and improve productivity.

Financial Analysis

Okay, let's get this Azenta, Inc. annual review ready for your friend!

Azenta, Inc. Annual Report - How They Did This Year

Hey there! So, you're thinking about investing in Azenta, Inc. or maybe you already have. Let's break down how they did this past year in a way that's easy to understand. Think of it like we're chatting over coffee about the company.

1. What does this company do and how did they perform this year?

Okay, so imagine Azenta as a company that helps other companies, especially in the healthcare and life sciences fields, with things like storing and managing biological samples (like blood or tissue) and providing automation solutions for research. Think of them as the behind-the-scenes helpers for scientists and researchers. They have two main business segments: Sample Management Solutions and Multiomics. Think of their "Core Products" as things like Automated Stores, Cryogenic Systems, Automated Sample Tubes, and Consumables and Instruments.

This year, we need to look at whether they helped more or less companies than last year, and whether those companies spent more or less money with Azenta. Did they expand their services? Did they win any big new clients? We'll dig into the specifics, but that's the general idea. Did they have a good year helping their customers, or did things slow down?

2. How much money did they make and is the business growing or shrinking?

This is the bottom line, right? We want to know if Azenta made a profit and if they're making more profit than last year. We'll look at their revenue (the total amount of money they brought in) and their net income (the profit after all expenses are paid).

  • Revenue: Think of this as the total sales. Did they sell more services and products this year than last year?
  • Net Income: This is the actual profit. After paying all the bills, how much money did Azenta actually keep?

We'll also see if the company is growing (making more money) or shrinking (making less). This is usually shown as a percentage change from the previous year. A positive percentage means growth, a negative percentage means they shrunk.

3. What were the biggest wins and challenges this year?

Every company has good news and bad news. We'll look at:

  • Wins: Did they launch a cool new product or service? Did they land a huge new customer? Did they expand into a new market? These are all good signs.
  • Challenges: Did they face any setbacks? Did they lose a major customer? Did they have problems with their supply chain? Did they have to deal with increased competition? These are things that could hurt their performance.

4. How do their finances look - are they healthy or struggling?

Think of this as checking the company's bank account and making sure they have enough money to pay their bills. We'll look at things like:

  • Cash on hand: How much money do they have readily available?
  • Debt: How much money do they owe? Too much debt can be a problem.
  • Assets: What do they own that's valuable (like equipment, buildings, or intellectual property)?

We want to see a company with plenty of cash, manageable debt, and valuable assets. It's also worth noting they deal with convertible debt securities, which are basically bonds that can be turned into stock under certain conditions.

5. What are the main risks that could hurt the stock price?

Every investment has risks. What could go wrong for Azenta? Maybe a competitor comes up with a better product. Maybe the economy slows down and companies cut back on research spending. Maybe there are changes in regulations that affect their business. We'll identify the biggest potential threats.

6. How do they compare to their competitors this year?

Are they the top dog in their industry, or are they struggling to keep up? We'll look at how Azenta performed compared to other companies that do similar things. Are they growing faster? Are they more profitable? This helps us understand if they're a good investment compared to other options.

7. Are there any major changes in leadership or strategy?

Did the CEO leave? Did they announce a big new plan for the future? Changes in leadership or strategy can have a big impact on a company's performance. We'll see if anything significant happened in this area. One thing to note is that they changed their operating segments on October 1, 2023, which might make comparing results to previous years a little tricky.

8. What should investors expect going forward?

What does Azenta think the future holds? Are they optimistic about their prospects? Are they expecting growth or are they bracing for challenges? We'll look at their guidance (what they're telling investors to expect) for the next year.

9. Any major market trends or regulatory changes affecting them?

Are there any big trends in the healthcare or life sciences industries that could help or hurt Azenta? Are there any new laws or regulations that they need to comply with? These external factors can play a big role in a company's success. Also, keep an eye on how changes in foreign exchange rates, especially in countries like China and Germany, might affect their earnings.

One more thing to keep in mind is that Azenta is working on a "transformation plan" to cut costs and improve productivity. They're spending money now on things like writing down old technology and redesigning processes, hoping it will pay off in the long run. These "transformation costs" are considered "non-recurring," meaning they shouldn't happen every year.

Okay, that's the overview! Now, let's dive into the details and see how Azenta actually performed this year. We'll break it all down so you can make an informed decision about whether or not to invest.

Risk Factors

  • Competition from other companies.
  • Economic slowdown impacting research spending.
  • Changes in regulations affecting their business.

Why This Matters

This 10-K filing for Azenta, Inc. is crucial for investors as it details the company's strategic pivot through a significant "transformation plan." This initiative aims to cut costs and boost productivity across its core Sample Management Solutions and Multiomics segments. Understanding the execution and impact of this plan is paramount, as it represents a substantial investment in future efficiency and profitability, even if it incurs "non-recurring" costs in the short term.

Furthermore, the report highlights a change in operating segments as of October 1, 2023, which will impact how investors compare current results to previous periods. This requires careful analysis to discern underlying performance trends from reporting adjustments. The company's financial health, including its cash position, debt levels (especially convertible debt securities), and exposure to foreign exchange fluctuations in key markets like China and Germany, provides a comprehensive picture of its operational stability and growth potential within the specialized healthcare and life sciences sectors.

What Usually Happens Next

Following this comprehensive 10-K annual report, investors should closely monitor Azenta's upcoming quarterly earnings reports (10-Q filings) and associated investor calls. These will provide the first updates on the progress and financial impact of the transformation plan. Key areas to scrutinize include whether the projected cost savings are materializing, if productivity improvements are evident, and if the "non-recurring" costs associated with the plan are indeed one-off or if they persist.

Investors should also watch for any revisions to Azenta's forward-looking guidance, which will reflect management's updated outlook on revenue, profitability, and capital expenditures in light of market conditions and transformation progress. Specific attention should be paid to the performance of the individual Sample Management Solutions and Multiomics segments, as well as any commentary on competitive dynamics, supply chain stability, and the impact of macroeconomic factors, including currency fluctuations. The next major milestone will be the release of the Q1 earnings, offering the first post-10-K snapshot of the company's trajectory.

Financial Metrics

Revenue Total sales of services and products.
Net Income Actual profit after all expenses are paid.
Growth Rate Percentage change in revenue or profit from the previous year.

Document Information

Analysis Processed

December 5, 2025 at 08:52 AM

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.